CN101623455B - Medicine for treating prostate hyperplasia - Google Patents
Medicine for treating prostate hyperplasia Download PDFInfo
- Publication number
- CN101623455B CN101623455B CN2009100176417A CN200910017641A CN101623455B CN 101623455 B CN101623455 B CN 101623455B CN 2009100176417 A CN2009100176417 A CN 2009100176417A CN 200910017641 A CN200910017641 A CN 200910017641A CN 101623455 B CN101623455 B CN 101623455B
- Authority
- CN
- China
- Prior art keywords
- parts
- grams
- radix
- medicine
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine for treating prostate hyperplasia, which is prepared from the following raw materials according to parts by weight: 10-20 parts of mulberry leaf, 10-20 parts of ginkgo leaf, 3-5 parts of gynostemma pentaphylla, 10-12 parts of wheat bran, 4-6 parts of evodia rutaecarpa, 6-8 parts of fructus citri sarcodactylis, 6-8 parts of herba eupatorii, 10-14 parts of wrinkled gianthyssop, 6-8 parts of officinal magnolia, 5-7 parts of inula flower, 4-6 parts of snakegourd fruit, 10-12 parts of red ginseng, 6-10 parts of radix salviae miltiorrhizae, 8-10 parts of red peony root, 8-10 parts of rhizoma ligustici wallichii, 12-14 parts of radix notoginseng, 8-10 parts of rhizoma corydalis, 10-14 parts of ophiopogon root and 8-10 parts of rosa banksiae. The invention has the advantages of small toxic or side effect, convenient taking, easy absorption, quick acting, good curative effect, low price and quick function and conforms to the national relevant standard by inspection. The clinical application observation confirms that the acting is quick. Compared with the traditional medicines, such as Qianliekang and the like, the traditional Chinese medicine preparation for treating the prostate hyperplasia disease has the characteristics of long acting, quick acting and high efficiency.
Description
(1) technical field
The present invention relates to a kind of medicine for the treatment of prostatic hyperplasia.
(2) background technology
Prostatic hyperplasia is a kind of frequently-occurring disease, during pilosity is born in, old comrade, shows as frequent micturition, the thin or dysuria of urine line, even urine retention, brings very big misery to the patient.The medicine of treatment prostatic hyperplasia is many based on oral medicine at present, but the course of treatment is long, easily recurrence, and the curative effect limitation, side effect is big, can not improve symptom all sidedly.Operative therapy is easy to generate serious complication, prostatic hyperplasia patient worn with age, and postoperative sickness rate and complication are more.Therefore still lack a kind of effective Comprehensive Treatment medicine at present for prostatic hyperplasia.
(3) summary of the invention
The present invention is in order to remedy the deficiencies in the prior art, provide that a kind of toxic and side effects is little, taking convenience, be easy to absorb, instant effect, good effect, price is low, prostatic hyperplasia is treated in effect rapidly medicine.
The present invention is achieved through the following technical solutions:
The medicine of treatment prostatic hyperplasia of the present invention, its special character is: the raw material by following parts by weight is made: Folium Mori 10-20 part, Folium Ginkgo 10-20 part, Herb Gynostemmae Pentaphylli 3-5 part, Testa Tritici 10-12 part, Fructus Evodiae 4-6 part, Fructus Citri Sarcodactylis 6-8 part, Herba Eupatorii 6-8 part, Herba Pogostemonis 10-14 part, Cortex Magnoliae Officinalis 6-8 part, Flos Inulae 5-7 part, Fructus Trichosanthis 4-6 part, Radix Ginseng Rubra 10-12 part, Radix Salviae Miltiorrhizae 6-10 part, Radix Paeoniae Rubra 8-10 part, Rhizoma Chuanxiong 8-10 part, Radix Notoginseng 12-14 part, Rhizoma Corydalis 8-10 part, Radix Ophiopogonis 10-14 part, Radix Aucklandiae 8-10 part, Flos Carthami 10-14 part, Radix Astragali 10-12 part, succinum 7-9 part, Cortex Cinnamomi 3-5 part, Os Draconis 6-8 part, Radix Angelicae Sinensis 10-14 part, Pollen Typhae 8-10 part, Fructus Schisandrae Chinensis 6-8 part, Semen Persicae 6-8 part, Lignum Aquilariae Resinatum 2-4 part, Concha Ostreae 6-8 part.
Preparation method: the said medicine that will need to arrange in pairs or groups is combined, and with Burdick lamp medicine is carried out sterilization processing; Then, put people's baking box to pharmaceutical drying, with pulverizer medicine is pulverized, be ground into the powder face then, restir is evenly packed in the hard capsule, packs.
Usage and dosage: every day three times, each five hard capsules, oral meal.
The invention has the beneficial effects as follows, toxic and side effects is little, taking convenience, be easy to absorption, instant effect, good effect, price is low, effect is rapid, meet relevant national standard through check, confirm instant effect through observation on Clinical Application, compare with traditional medicines such as QIANLIEKANG, the Chinese medicine preparation of this treatment hyperplasia of prostate has long-acting, quick-acting and characteristics of high efficiency, and some patient takes medicine surplus in the of 20 and day promptly to heal, and follows up a case by regular visits to a year and a half and does not see recurrence.
(4) specific embodiment
Embodiment 1
The medicine of treatment prostatic hyperplasia of the present invention is made by the raw material of following weight: Folium Mori 15 grams, Folium Ginkgo 15 grams, Herb Gynostemmae Pentaphylli 4 grams, Testa Tritici 11 grams, Fructus Evodiae 5 grams, Fructus Citri Sarcodactylis 7 grams, Herba Eupatorii 7 grams, Herba Pogostemonis 12 grams, Cortex Magnoliae Officinalis 7 grams, Flos Inulae 6 grams, Fructus Trichosanthis 5 grams, Radix Ginseng Rubra 11 grams, Radix Salviae Miltiorrhizae 8 grams, Radix Paeoniae Rubra 9 grams, Rhizoma Chuanxiong 9 grams, Radix Notoginseng 13 grams, Rhizoma Corydalis 9 grams, restrain Radix Ophiopogonis 12, the Radix Aucklandiae 9 grams, Flos Carthami 12 grams, the Radix Astragali 11 grams, succinum 8 grams, Cortex Cinnamomi 4 grams, Os Draconis 7 grams, Radix Angelicae Sinensis 12 grams, Pollen Typhae 9 grams, Fructus Schisandrae Chinensis 7 grams, Semen Persicae 7 grams, Lignum Aquilariae Resinatum 3 grams, Concha Ostreae 7 grams.
Preparation method: the said medicine that will need to arrange in pairs or groups is combined, and with Burdick lamp medicine is carried out sterilization processing; Then, put people's baking box to pharmaceutical drying, with pulverizer medicine is pulverized, be ground into the powder face then, restir is evenly packed in the hard capsule, packs.
Usage and dosage: every day three times, each three hard capsules, oral meal, one month is a course of treatment.
Embodiment 2
The medicine of treatment prostatic hyperplasia of the present invention is made by the raw material of following weight: Folium Mori 10 grams, Folium Ginkgo 10 grams, Herb Gynostemmae Pentaphylli 3 grams, Testa Tritici 10 grams, Fructus Evodiae 4 grams, Fructus Citri Sarcodactylis 6 grams, Herba Eupatorii 6 grams, Herba Pogostemonis 10 grams, Cortex Magnoliae Officinalis 6 grams, Flos Inulae 5 grams, Fructus Trichosanthis 4 grams, Radix Ginseng Rubra 10 grams, Radix Salviae Miltiorrhizae 6 grams, Radix Paeoniae Rubra 8 grams, Rhizoma Chuanxiong 8 grams, Radix Notoginseng 12 grams, Rhizoma Corydalis 8 grams, restrain Radix Ophiopogonis 10, the Radix Aucklandiae 8 grams, Flos Carthami 10 grams, the Radix Astragali 10 grams, succinum 7 grams, Cortex Cinnamomi 3 grams, Os Draconis 6 grams, Radix Angelicae Sinensis 10 grams, Pollen Typhae 8 grams, Fructus Schisandrae Chinensis 6 grams, Semen Persicae 6 grams, Lignum Aquilariae Resinatum 2 grams, Concha Ostreae 6 grams.
All the other are identical with embodiment 1.
Embodiment 3
The medicine of treatment prostatic hyperplasia of the present invention is made by the raw material of following weight: Folium Mori 20 grams, Folium Ginkgo 20 grams, Herb Gynostemmae Pentaphylli 5 grams, Testa Tritici 12 grams, Fructus Evodiae 6 grams, Fructus Citri Sarcodactylis 8 grams, Herba Eupatorii 8 grams, Herba Pogostemonis 14 grams, Cortex Magnoliae Officinalis 8 grams, Flos Inulae 7 grams, Fructus Trichosanthis 6 grams, Radix Ginseng Rubra 12 grams, Radix Salviae Miltiorrhizae 10 grams, Radix Paeoniae Rubra 10 grams, Rhizoma Chuanxiong 10 grams, Radix Notoginseng 14 grams, Rhizoma Corydalis 10 grams, restrain Radix Ophiopogonis 14, the Radix Aucklandiae 10 grams, Flos Carthami 14 grams, the Radix Astragali 12 grams, succinum 9 grams, Cortex Cinnamomi 5 grams, Os Draconis 8 grams, Radix Angelicae Sinensis 14 grams, Pollen Typhae 10 grams, Fructus Schisandrae Chinensis 8 grams, Semen Persicae 8 grams, Lignum Aquilariae Resinatum 4 grams, Concha Ostreae 8 grams.
All the other are identical with embodiment 1.
Embodiment 4 clinical observations:
The present invention carries out clinical observation treatment to 240 routine male patients, and the age 34 was prostatic hyperplasia, hypertrophy to 70 years old, shows as frequent micturition, the thin or dysuria of urine line, even urine retention.Every day three times, each three hard capsules, oral meal, one month is a course of treatment.
(1) efficacy assessment standard:
Cure: the clinical symptoms sign disappears, and it is normal that functional activity recovers.
Produce effects: the basic or big portion of clinical symptoms sign disappears.
Effectively: clinical symptoms is clearly better or takes a turn for the better.
Invalid: the clinical symptoms sign does not have improvement.
(2) therapeutic effect:
Clinical cure 226 examples account for 94%; Produce effects 12 examples account for 5%; Effective 2 examples account for 1%; Total effective rate 100%.Wherein, among the healing person, cure 78 examples a course of treatment with interior healing 85 examples on 20th, cure 48 examples two courses of treatment, cure 15 examples three courses of treatment.
Model case is as follows:
1. king's stannum honor, 58 years old, the peasant, dark county position bridge township Jiao Cun came my out-patient department to go to a doctor on November 26th, 2005, frequent micturition is not smooth, dysuria 5 years surplus, once took QIANLIEKANG.Suddenly increased the weight of before ZO days, urine reaches IO night surplus time frequently, and amount is dripping shape, lower abdominal distention pain, enuresis nocturna less.Be diagnosed as prostatic hyperplasia, chronic urinary retention.Take medicine of the present invention, symptom takes a turn for the better after taking medicine 2 days, and urine is unobstructed after 6 days, and lower abdominal distention pain obviously alleviates, and continues to take medicine month surplus and heals.Follow up a case by regular visits to and do not see recurrence so far.
2. Zhai's distant mountain, 71 years old, the workman, trouble township, Zaoqiang County Calculus Bovis from Northwest of China Pu village came the outpatient service diagnosis and treatment on the 14th in December in 2007, and not smooth 1 year of patient's frequent micturition is surplus; urine often, bradyuria, the urine line is thin; trouble urinating, local medication fails to respond to any medical treatment my out-patient treatment, is diagnosed as prostatic hyperplasia and prostatitis; take medicine of the present invention; symptom disappears substantially after 3 days, continues to take medicine surplus in the of 20 day promptly to heal, and follows up a case by regular visits to so far recurrence.
Claims (1)
1. medicine for the treatment of prostatic hyperplasia, it is characterized in that: the raw material by following parts by weight is made: Folium Mori 10-20 part, Folium Ginkgo 10-20 part, Herb Gynostemmae Pentaphylli 3-5 part, Testa Tritici 10-12 part, Fructus Evodiae 4-6 part, Fructus Citri Sarcodactylis 6-8 part, Herba Eupatorii 6-8 part, Herba Pogostemonis 10-14 part, Cortex Magnoliae Officinalis 6-8 part, Flos Inulae 5-7 part, Fructus Trichosanthis 4-6 part, Radix Ginseng Rubra 10-12 part, Radix Salviae Miltiorrhizae 6-10 part, Radix Paeoniae Rubra 8-10 part, Rhizoma Chuanxiong 8-10 part, Radix Notoginseng 12-14 part, Rhizoma Corydalis 8-10 part, Radix Ophiopogonis 10-14 part, Radix Aucklandiae 8-10 part, Flos Carthami 10-14 part, Radix Astragali 10-12 part, succinum 7-9 part, Cortex Cinnamomi 3-5 part, Os Draconis 6-8 part, Radix Angelicae Sinensis 10-14 part, Pollen Typhae 8-10 part, Fructus Schisandrae Chinensis 6-8 part, Semen Persicae 6-8 part, Lignum Aquilariae Resinatum 2-4 part, Concha Ostreae 6-8 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100176417A CN101623455B (en) | 2009-08-13 | 2009-08-13 | Medicine for treating prostate hyperplasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100176417A CN101623455B (en) | 2009-08-13 | 2009-08-13 | Medicine for treating prostate hyperplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101623455A CN101623455A (en) | 2010-01-13 |
| CN101623455B true CN101623455B (en) | 2011-01-19 |
Family
ID=41519550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100176417A Expired - Fee Related CN101623455B (en) | 2009-08-13 | 2009-08-13 | Medicine for treating prostate hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101623455B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526623B (en) * | 2012-02-05 | 2013-06-19 | 孔德宝 | Preparation method of traditional Chinese medicine for treating qi-blood stasis stagnant type prostatitis |
| CN104474457B (en) * | 2014-11-20 | 2017-12-22 | 界首骨科医院 | A kind of Chinese medicine composition of external application for curing hyperplasia of prostate |
| JP2021530454A (en) * | 2018-06-29 | 2021-11-11 | ジーイー ニュートゥリエンツ, インコーポレイテッドGe Nutrients, Inc. | Medicinal plant extract compositions and methods for ameliorating and managing benign prostatic hyperplasia (BPH) and related aging symptoms using extracts from Ageratum spp. |
-
2009
- 2009-08-13 CN CN2009100176417A patent/CN101623455B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101623455A (en) | 2010-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102302751B (en) | Chinese medicine for treating migraine | |
| CN103385986B (en) | Chinese medicine tincture for treating leucoderma | |
| CN102727779B (en) | Pharmaceutical composition for treating ovarian cysts and preparation method thereof | |
| CN101623455B (en) | Medicine for treating prostate hyperplasia | |
| CN102600426A (en) | Chinese medicinal preparation for promoting blood circulation to remove blood stasis and preparation method thereof | |
| CN101912567B (en) | Chinese medicinal prescription for treating chronic myocarditis | |
| CN101204532B (en) | Medicine for prostate disease and preparation method thereof | |
| CN103330928B (en) | Traditional Chinese medicine composition used for treating gastric ulcer and preparation method thereof | |
| CN102600351B (en) | Traditional Chinese medicine for treating pruritus cutanea | |
| CN101491612B (en) | Medicine for treating mammary hyperplasia and early breast cancer | |
| CN103055055A (en) | Traditional Chinese medicine for treating skin diseases | |
| CN101843778B (en) | Chinese medicament for treating ichthyosis | |
| CN102210846B (en) | Medicament for treating dysmenorrhea | |
| CN102228591A (en) | Preparation method of oral medicinal preparation for regulating menstruation and stopping pains | |
| CN101810831B (en) | Medicament for treating gynecological diseases | |
| CN101664459A (en) | Hemorrhoid neixiaodan | |
| CN103656492A (en) | Traditional Chinese medicine for external use for treating headache | |
| CN103638149A (en) | Traditional Chinese medicine composition for treating rectal cancer | |
| CN103638259A (en) | Traditional Chinese medicine pill for treating liver stagnation type irregular menstrual period | |
| CN103142972B (en) | Medicine for treating children dermatosis | |
| CN101961387A (en) | Traditional Chinese medicine for treating diabetic skin pruritus | |
| CN103110710B (en) | Traditional Chinese medicine pill for treating spontaneous perspiration | |
| CN104800599A (en) | Traditional Chinese medicinal composition for treating deficiency of kidney-yin | |
| CN103800809A (en) | Traditional Chinese medicinal preparation for treating liver diseases | |
| CN1669569A (en) | Medicine for dispelling tinea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110119 Termination date: 20110813 |